WEST CHESTER, PA — Molecular Targeting Technologies, Inc. (MTTI) has unveiled significant preclinical results for its proprietary Ac-EBTATE radiopharmaceutical, demonstrating remarkable efficacy against somatostatin receptor-2-positive neuroendocrine tumors (NETs), including small cell lung cancer (SCLC). Details of the study have been published in the European Journal of Nuclear Medicine (https://rdcu.be/d2lCG).
Lead researcher Professor Humphrey Fonge from Université de Laval highlighted the groundbreaking findings. “At just 40% of the administered dose reported for Ac-DOTATATE, Ac-EBTATE produces enhanced anti-tumor efficacy in small cell lung cancer (SCLC) and Pan-neuroendocrine tumor (NET) models as shown with complete tumor remissions,” Fonge said. He also noted that at a therapeutic dose of 2x 34 kBq, Ac-EBTATE not only achieved an 80% complete remission rate but also ensured 100% survival in preclinical models. Safety analysis over 28 days indicated no concerning effects, based on blood biochemistry, complete blood count (CBC), and histopathological results.
MTTI’s technology is built on the patented Evans blue (EB) platform licensed from the National Institutes of Health (NIH). The EB component binds to serum albumin, increasing the half-life of the radiopharmaceutical and boosting its tumor-targeting capabilities by as much as 30 times. This innovation allows Ac-EBTATE to achieve high efficacy at significantly lower doses and with fewer treatment cycles compared to current standards.
MTTI has already documented promising outcomes in related therapies. A three-year follow-up study of Lu-EBTATE in 30 patients with metastatic neuroendocrine tumors demonstrated a 40% reduction in administered dose compared to Lu-DOTATATE, with no kidney or liver toxicity and an 86% disease control rate.
Dr. Jean-Mathieu Beauregard, Associate Professor at Université de Laval, expressed optimism about transitioning Ac-EBTATE into clinical trials. “I am encouraged to see the positive results of Ac-EBTATE in treating small cell lung cancer and Pan-neuroendocrine tumor (NET) in preclinical studies. I look forward to working with MTTI and Professor Fonge to translate this into the clinic,” he said.
MTTI’s President and CEO, Dr. Chris Pak, echoed this enthusiasm. “Ac-EBTATE effectiveness was encouraging, paralleling the clinical superiority of Lu-EBTATE. We look forward to collaborating with Professors Beauregard and Fonge to drive Ac-EBTATE into clinical trials in 2025.”
With its focus on next-generation targeted radiopharmaceuticals, MTTI continues to develop pioneering solutions for cancer treatment. Ac-EBTATE’s promising preclinical results set the stage for further innovations aimed at improving patient outcomes with safer, more efficient therapies.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.